Discussing clinical evidence, Oyler pointed to data presented at ASH 2025 in frontline chronic lymphocytic leukemia (CLL), including six-year progression-free survival of 74% and overall survival of 84%, with adjusted figures of 77% and 87%, respectively, when accounting for COVID. He also highlighted long-term landmark progression-free survival comparisons across trials, while noting cross-trial limitations.Oyler emphasized the commercial and clinical trajectory of BRUKINSA, which he described as having “f ...